posted
This stock is breaking out of it trading range finally. resistance was at .048 and .050 broke through that and finally hit resistance at .053. could be a show stopper in late afternoon pay attention to it. With the new bill in process again dems are heating up the stem sector.
IP: Logged |
posted
Spread is now tight .052x.053 testing new high. All the stem stocks are doing good. Volume is amazing heres a chart. Good entries if your still not in yet. Im predicting the mid .06's by next week. With this type of momo. You gotta know how to play thes bulls lets get ready to make some cash.
oh yea u guys sleeping out there lolz
-------------------- Hustler is a hustler a customer is a customer
IP: Logged |
posted
Chart setup here...I have been fairly pleased with the bullishness of CLBE lately...Although it hasn't moved like some of the other stems it seems to be churning through some of those negative shareholders and getting them into tighter hands...
-------------------- Hustler is a hustler a customer is a customer
IP: Logged |
posted
it is a good entry position as u can see volume came in but closed down. so its still a good entry IMO we will go way higher as u can see the tail on top of the candle. Wait until monday. We also have a PR that were expecting. The past two years they released the PR on December 28. But not this year so it should be out anytime now. Every PR they get more profitable.
-------------------- Hustler is a hustler a customer is a customer
IP: Logged |
posted
Like i had said previously this stock is due for a major bounce. Below i will be posting a cycle that alot of people are following and expecting for a bounce say sometime in the first two weeks of january. This stock has been accumulating at these low levels for a while and they're due for a PR also, so it's due for an outbreak on the upside. The PR will have info about profitible futures and profit they have made since the last PR.
Here you can do some DD if your not familiar with this company!!
LifeStem:http://www.domainsnext.com/comingsoo...n=lifestem.com CLBE web site: http://www.calbatech.com/ Headlines:http://finance.yahoo.com/q/h?s=CLBE.OB Sec Files:http://www.sec.gov/cgi-bin/browse-ed...&State=&SIC=&o.... Quarterly Income Data:http://finance.yahoo.com/q/is?s=CLBE.OB
These are all valid reasons to enter here at these low prices.
1) Patents assigned any day now 2) The announcement they are green for 2006 3) Government or private fundings (this has a thin market cap, remember) 4) Better than expected financial results 5) A big success of their banking platform 6) A media important person that choose LifeStem for banking is Stem Cell 7) Some big news on adult StemCells 8) A buyout
This can go over a buck easy!! and im serious!!
and thats only one single division....theres a lot more going on within this company then most realize and some are predicting multiple dollar range in the near future.the CEO has stated and I posted here on HSM that they do intend on moving to the big boards in the future and that was just about a year ago.In order for them to move up they already know they need a higher PPS and I think in 2007 thats going to be priority.they clearly said they will not do a RS to raise the PPS to qualify and they said they don't plan on raising the AS either since th company is already self supporting from income......now think about the math....only 97 mill OS and only 200 mill AS,thats only about 103 million shares that they intend to add and thats if needed.....see how easy this could run to insane levels with the right news and maybe institutional buying? just watch for a major announcement concerning a big board partner and see where this puppy runs to! and 3 patents pending to.....that would require other stem cell companies to purchase licenses from Calbatech....imagine that
-------------------- Hustler is a hustler a customer is a customer
IP: Logged |
CalbaTech Announces Increase in Revenue for Nine Months; LifeStem Continuing to Enroll New Medspas to Sell Its Stem Cell MicroBank(TM) Service Wednesday November 15, 4:00 am ET - $3.58 Million Projection for Revenues for First Year Banking Services -
IRVINE, Calif., Nov. 15 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE - News), an emerging life sciences company (http://www.CalbaTech.com) concentrating on banking adult stem cells for possible future therapeutic uses and providing products and platforms to the biotech and pharmaceutical research markets and to academic institutions, today announced that revenues for the first nine months ended September 30, 2006 totaled $977,444, up three percent compared to the same period in 2005. ADVERTISEMENT
Net income for the first nine months of 2006 totaled $629,822, or $0.01 per share, compared to a loss in 2005. The net income reported is because of the unrealized gain on adjustment of derivative and warrant liabilities to fair value of the underlying securities relating to the convertible notes CalbaTech obtained in 2005. CalbaTech posted a gross profit of $579,443 for the nine month period, compared to a gross profit of $449,330 for the first nine months of 2005.
The Company also announced a significant decrease in operating expenses, from $1.72 million for the nine months ended September 30, 2005 to $1.33 million for the same period in the current year. "We continue to be successful in cutting costs and increasing profitability," said James DeOlden, CEO.
In its Form 10-QSB filing, CalbaTech said its wholly-owned subsidiary, LifeStem, (www.life-stem.com) has moved ahead with its roll-out of the Stem Cell MicroBank(TM) Service, collecting adult stem cells for possible future needs, through the Solana Medspas network. LifeStem has begun marketing its service, providing marketing materials to the individual medspas, and has begun providing training to the medspa personnel. In a major positive development, Solana Medspas has entered into a letter of intent with a partner to open 4,000 additional medspas throughout the country within the next four years, all of which potentially would carry LifeStem's banking services.
"LifeStem is conservatively projecting $3.858 million in revenues in the first 12 months of operation and $26.3 million during its second 12 months," Mr. DeOlden said. "While we have not processed any clients yet, it is not because of lack of interest. We have received requests for subscription packets, have begun hosting seminars to potential clients, and our Chief Medical Officer, Dr. Jason Van Tassel, M.D. appeared on the radio and the Internet to discuss our service to a significant listening audience. Some of the regulatory, logistical and training issues have taken longer than anticipated, but this is to be expected in a new breakthrough service such as ours."
Mr. DeOlden continued, "The therapeutic possibilities that may be provided by collecting and preserving healthy adult stem cells on a pre-disease basis could revolutionize the practice of medicine. The market for stem cell technology has been estimated to grow to $30 billion by the year 2010."
About CalbaTech
CalbaTech, Inc. (OTC Bulletin Board: CLBE - News) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions. CalbaTech's wholly owned subsidiary LifeStem has developed a unique process to harvest stem cells in micro quantities to be cryopreserved for future transplantation into a client for medical purposes. The collection of stem cells from two different tissue sources increases the potential for treatment of more diseases.
-------------------- Hustler is a hustler a customer is a customer
IP: Logged |
IRVINE, Calif., Jan. 12 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com ) concentrating on banking adult stem cells for possible future therapeutic uses and providing products and platforms to the biotech and pharmaceutical research markets and to academic institutions, today said it supports the U.S. House of Representatives for approving a bill to increase the spending of Federal research dollars for stem cell research.
CalbaTech also cited recent research by Robin Young Consulting Group that predicts that sales of adult stem cell products will more than double in 2007, exceeding $35 million, and then explode to more than $175 million in sales by 2009. 'Big growth,' Mr. Young told United Press International, 'will excite capital markets and we should expect to see a fair amount of capital coming in to help support these companies.'
'We are confident we are in the right place at exactly the right time with our unique adult stem cell collection process,' said CalbaTech CEO James DeOlden. 'As the House of Representatives moves forward with its commitment to funding stem cell research, and with the predicted capital markets being invigorated by the expected explosive revenues for the adult stem cell sector, adult stem cell businesses, like the Stem Cell MicroBank(TM) Service of our wholly-owned subsidiary LifeStem(TM), will see a significant, direct benefit.'
Dr. Jason R. Van Tassel, M.D., Chief Medical Officer of LifeStem(TM) stressed that, 'The therapeutic possibilities that may be provided by collecting and preserving healthy adult stem cells on a pre-disease basis could revolutionize the practice of medicine.'
Investors and prospective clients interested in LifeStem's Stem Cell MicroBank(TM) Service should visit the web site (www.life-stem.com) for more information.
About CalbaTech
CalbaTech, Inc. (OTC Bulletin Board: CLBE) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions. CalbaTech's wholly owned subsidiary LifeStem has developed a unique process to harvest stem cells in micro quantities to be cryopreserved for future transplantation into a client for medical purposes. The collection of stem cells from two different tissue sources increases the potential for treatment of more diseases.
Contact: Paul Knopick E&E Communications (949) 707-5365 pknopick*eandecommunications.com
Note: Certain statements in this news release may contain 'forward-looking' information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. We use words such as 'anticipate,' 'believe,' 'expect,' 'future,' 'intend,' 'plan,' and similar expressions to identify forward-looking statements. These statements including those related to being in a large and growing market, exhibiting rapid growth characteristics, and having a growth strategy, are forward looking statements. These forward looking statements are only predictions and are subject to certain risks, uncertainties and assumptions. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or assumptions in this press release include the risk that we will not be able to grow our revenues and market share, the risk that our prices do not remain competitive and the risk that we will not achieve profitability. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission, including our most recent Report on Form 10-KSB, and Reports on Form 10-QSB and Form 8-K. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims, any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
SOURCE CalbaTech, Inc.
Source: PR Newswire (January 12, 2007 - 5:00 AM EST)
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Big Grin]](biggrin.gif)
